Format

Send to

Choose Destination
Food Sci Biotechnol. 2017 Dec 12;27(3):853-857. doi: 10.1007/s10068-017-0296-7. eCollection 2018 Jun.

Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial.

Author information

1
1Department of Food Science and Technology, Seoul National University of Science and Technology, Seoul, 01811 Korea.
2
2Department of Nutritional Science and Food Management, Ewha Womans University, Seoul, 03760 Korea.

Abstract

Lactobacillus gasseri BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect of Lb. gasseri BNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/m2 were randomized to intake a placebo, low-dose (BNR-L, 2 × 108 CFU/day), intermediate-dose (BNR-M, 2 × 109 CFU/day), or high-dose BNR (BNR-H, 2 × 5 × 109 CFU/day) for four weeks. Questionnaire for IBS symptoms scores and Lb. gasseri BNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group. Lb. gasseri BNR17 was detected in all intake groups except placebo. In the preliminary study, Lb. gasseri BNR17 was confirmed to have probiotic properties.

KEYWORDS:

Irritable bowel syndrome; Lactobacillus gasseri BNR17; Probiotics

Conflict of interest statement

Compliance with ethical standardsThe authors declare that they have no conflict of interest.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center